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Supplementary Figures 
 
Supplementary Figure 1: Genome-wide Manhattan plot for internal cIMT.  
Genome-wide Manhattan plot showing the individual p-values (based on discovery meta-analysis) against their 
genomic position for internal carotid IMT. Within each chromosome, shown on the x-axis, the results are plotted 
left to right from the p-terminal end. The solid line indicates the threshold for follow-up, p<4 ×10-7 , the dashed 
line indicates the threshold for genome-wide significance, p<5 ×10-8. 
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Supplementary Figure 2: Regional plot for suggestive common carotid IMT locus.  
 
Plots are centered on the most significant SNP at locus along with the meta-analysis results for SNPs in the 
100kb region surrounding it. All SNPs are plotted with their discovery meta-analysis p-values against their 
genomic position, with the most significant SNP in the region indicated as a diamond and other SNPs shaded 
according to their pairwise correlation (r2) with the signal SNP. The light blue line represents the estimated 
recombination rates. Gene annotations are shown as dark green lines. 
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Supplementary Figure 2: Regional plot for suggestive common carotid IMT locus.
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Supplementary Figure 3: Regional plots for suggestive plaque loci.  
Plots are centered on the most significant SNP at each locus along with the meta-analysis results for SNPs in the 
100kb region surrounding it. All SNPs are plotted with their discovery meta-analysis p-values against their 
genomic position, with the most significant SNP in the region indicated as a diamond and other SNPs shaded 
according to their pairwise correlation (r2) with the signal SNP. The light blue line represents the estimated 
recombination rates. Gene annotations are shown as dark green lines. 
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Supplementary Figure 3: Regional plots for suggestive plaque loci.
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated 
with carotid intima media thickness and plaque. (Supplementary Note) 
 
  7 
Supplementary Figure 4: Forest plot for suggestive common carotid IMT SNP association.  
Plots show the study-specific association estimates (β) and 95% confidence intervals for the nine discovery and 
second stage studies, presented as bars. The scale is ln(cIMT). The association estimate and confidence interval 
for the meta-analysis combining discovery and second stage results is presented as a diamond. Blank spaces 
indicate occasions in which a particular study was not able to provide results for a given SNP. 
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Supplementary Figure 5: Forest plots for suggestive plaque SNP associations.  
Plots show the study-specific association estimates (OR) and 95% confidence intervals for the nine 
discovery and second stage studies, presented as bars. The association estimate and confidence interval 
for the meta-analysis combining discovery and second stage results is presented as a diamond. Blank 
spaces indicate occasions in which a particular study was not able to provide results for a given SNP. 
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Supplementary Figure 6: common cIMT by 4 SNP gene score.  
Each of the nine discovery studies created a gene score, a sum of the number of alleles for the genomewide significant 
and suggestive SNPs from our analysis of common cIMT, coding the SNPs in terms of the allele associated with higher 
common cIMT in the meta-analysis. We present the mean common cIMT from each study according to categories of 
the gene score.  
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Supplementary Tables 
Supplementary Table 1: Published evidence for heritability of carotid artery phenotypes 
Study Common cIMT Internal cIMT Carotid Plaque Sample Size Ethnicity 
 Minimally 
adjusted 
(%) 
Risk 
factor 
adjusted 
(%) 
Minimally 
adjusted 
(%) 
Risk 
factor 
adjusted 
(%) 
Minimally 
adjusted 
(%) 
Risk 
factor 
adjusted 
(%) 
N persons/ 
N families 
 
 
European Ancestry  
Zannad 19981  33     315/76 French  
Jartti 2002 2 36      -/74 twin pairs Finnish  
Fox 2003 3 67 38 43 35   906/586 US  
Swan 2003 4 31      -/264 twin pairs British  
Moskau 2005 5  61    47*,  26** 556/154 German  
Mayosi 2005 6. 24      854/224 British  
Sayed-Tabatabaei 2005 7 41 34     930/1 Dutch  
Ryabikov 2007 8  54     286/81 Russian  
Rampersaud 2008 9 29 25     478/279 US Amish 
 
European Ancestry & African Americans 
Lange 2002 10 32 41     252/122 US (T2DM) 
Zhao 2008 11. 69 59     -/98 twin pairs US  
 
Hispanic Ancestry  
        
Duggirala 1996 12 86 92 87 86   88/46 Mexican  
Hunt 2002 13     28 23 750/29 Mexican Amer. 
Juo 200414 39  12    440/77 Carribean  
Wang 2005 15 45 40     413/91 Mexican Amer.  
Kao 2005 16 16      620/24 Mexican Amer.  
Xiang 2002 17  72 64     286/54 Multiple H (HTN) 
Sacco 2009 18, Dong 2010 19  65    50 <=1390/100 Dominican H 
 
Native Americans  
North 2002 20  21     950/32 Native American 
Table modified from Manolio et al, 2004. 21 
*Heritability of plaque=carotid stenosis; ** Heritability of plaque=carotid stenosis, adjusted for common cIMT.   
Abbreviations: cIMT=carotid intimal medial thickness, US=United States, T2DM=type 2 diabetes mellitus, HTN=hypertensio 
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Supplementary Table 2: Correlation between carotid phenotypes in ARIC, CHS, and FHS 
 
Correlation: Common cIMT 
& Internal cIMT 
Common cIMT  
&  Plaque 
Internal cIMT  
& Plaque 
ARIC 0.36 0.39 0.60 
CHS 0.67 0.27 0.43 
FHS 0.49 0.36 0.52 
Note: Study-specific Pearson correlation coefficients, shown above, were calculated using 
natural-log transformed values for the continuous phenotypes of common and internal 
cIMT.  
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Supplementary Table 3: Discovery, Second stage, and Combined meta-analysis for common cIMT and plaque, suggestive loci 
    
Discovery GWAS  
(cIMT)  
Second Stage Meta-analysis  
(cIMT)  
Combined Meta-analysis 
(cIMT) 
SNP Chr 
Nearest 
gene Alleles AF β SE N  p-value   AF β SE N  
p-
value   β SE p-value 
rs4712972 6 SLC17A4 A/G 0.12 0.0121 0.0023 30,565 9.8×10-8   0.12 0.0056 0.0031 10,394 0.1   0.0099 0.0018 7.8×10-8 
                   
    Discovery GWAS 
(plaque) 
 Second Stage Meta-analysis  
(plaque) 
 Combined Meta-analysis 
(plaque) 
SNP Chr 
Nearest 
gene Alleles AF OR (95% CI) N  p-value   AF OR (95% CI) N  
p-
value   OR (95% CI) p-value 
rs6511720 19 LDLR T/G 0.13 0.83 (0.77 - 0.89) 18,671 8.2×10-8   0.05 0.92 (0.76 - 1.12) 4,281 0.4   0.84 (0.78 - 0.89) 1.0×10-7 
rs17045031 3 LRIG1 A/G 0.03 0.70 (0.61 - 0.79) 22,076 3.2×10-8   0.04 0.97 (0.74 - 1.25) 5,820 0.8   0.74 (0.66 - 0.83) 3.8×10-7 
 
Alleles indicates the coded (named first) & non-coded allele; AF indicates allele frequency for the coded allele, an average weighted by study size; OR indicates odds ratio, CI, 
confidence interval; N indicates effective sample size, calculated by taking the sum of each study’s sample size multiplied by the SNP’s imputation quality. When more than one 
SNP at a locus surpassed our p-value threshold, we presented the SNP with the lowest p-value. 
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Supplementary Table 4: Discovery meta-analysis for internal cIMT 
SNP Chr Position 
Closest 
Gene Alleles AF β SE p-value N 
rs10276782 7 24771765 DFNA5 T/C 0.11 -0.0550 0.0113 1.0×10-6 7392 
rs9823028 3 1165111 CNTN6 A/G 0.01 0.2326 0.0481 1.3×10-6 3602 
rs2773822 9 134850854 GFI1B T/C 0.12 -0.0507 0.0105 1.4×10-6 5912 
rs2275292 20 62131496 PRPF6 T/C 0.87 0.0731 0.0162 6.5×10-6 2709 
rs10815111 9 4901930 RCL1 T/C 0.6 -0.0245 0.0054 7.1×10-6 10844 
rs17090381 13 73197831 KLF12 T/C 0.98 -0.0922 0.0206 7.9×10-6 9516 
rs11864736 16 63818912 LOC283867 A/C 0.12 0.0365 0.0082 8.0×10-6 10641 
rs7195314 16 63816846 LOC283867 T/C 0.12 0.0363 0.0082 8.3×10-6 10685 
rs1037232 12 75866037 CSRP2 A/G 0.01 0.1657 0.0373 8.9×10-6 5288 
Alleles indicate coded (named first) & non-coded alleles; AF indicates allele frequency for the coded allele; 
N indicates effective sample size, calculated by taking the sum of each study’s sample size multiplied by the 
SNP’s imputation quality 
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Supplementary Table 5: Comparison of meta-analysis results for common cIMT, plaque, and internal cIMT 
(A) Top SNPs from the combined discovery and second stage meta-analysis of common cIMT  
    Combined common cIMT analysis  Combined plaque analysis  Discovery internal cIMT analysis 
SNP Chr Alleles Closest 
gene 
β SE N p-value   OR (95% CI) N p-value   β SE N p-value 
rs11781551 8 a/g ZHX2 -0.0078 0.0012 41,295 2×10-11  0.96 (0.93 – 1.00) 30,968 0.05  -0.0132 0.0054 10,769 0.02 
rs445925 19 a/g APOC1 -0.0156 0.0028 17,185 2×10-8  0.82 (0.76 - 0.89) 14,097 4×10-6  -0.0466 0.0151 2,939 0.002 
rs6601530 8 g/a PINX1 0.0078 0.0014 32,631 2×10-8  1.09 (1.04 - 1.14) 22,629 0.0001  0.0130 0.0062 9,039 0.03 
rs4712972 6 a/g SLC17A4 0.0099 0.0018 40,959 8×10-8   1.09 (1.02 - 1.15) 30,690 0.006   -0.0012 0.0082 10,486 0.9 
 
(B) Top SNPs from the combined discovery and second stage meta-analysis of plaque  
 
    Combined common cIMT analysis  Combined plaque analysis  Discovery internal cIMT analysis 
SNP Chr Alleles Closest 
gene 
β SE N p-value   β SE N p-value   β SE N p-value 
rs17398575 7 a/g PIK3CG 0.0067 0.0014 37,533 3×10-6  0.1619 0.0231 29,255 2×10-12  0.0199 0.0066 10,356 0.002 
rs1878406 4 t/c EDNRA 0.0087 0.0018 38,071 7×10-7  0.1993 0.0291 29,827 7×10-12  0.0260 0.0083 10,201 0.002 
rs6511720 19 t/g LDLR -0.0065 0.0022 26,649 0.003  -0.1778 0.0334 22,952 1×10-7  -0.0236 0.0010 6,875 0.02 
rs17045031 3 a/g LRIG1 -0.0033 0.0036 34,090 0.4   -0.2986 0.0588 27,896 4×10-7   0.0136 0.0184 8,000 0.5 
Table shows results from the meta-analysis of the combined discovery and second stage for common cIMT and plaque; results for internal cIMT represent 
discovery findings since no internal cIMT SNPs were carried on to the second stage. Alleles indicates the coded & non-coded allele; AF indicates allele 
frequency for the coded allele, an average weighted by study size; N (eff) indicates effective sample size, calculated by taking the sum of each study’s sample size 
multiplied by the SNP’s imputation quality. 
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Supplementary Table 6: Meta-analysis results for common cIMT, plaque, and internal cIMT for 
23 SNPs replicated or identified by the CARDIoGRAM Consortium 
    Common cIMT Plaque Internal cIMT 
SNP Band Genes 
Risk 
Allele β p-value OR p-value β p-value 
rs599839 1p13.3 SORT1 A 0.0015 0.4 1.07 0.005 0.0137 0.04 
rs17114036 1p32.2 PPAP2B T 0.0061 0.02 1.05 0.2 -0.0025 0.8 
rs11206510 1p32.3 PCSK9 A 0.0001 1.0 1.04 0.2 0.0100 0.2 
rs17465637 1q41 MIA3 C n/a n/a n/a n/a n/a n/a 
rs6725887 2q33.1 WDR12 C 0.0015 0.5 1 1.0 0.0001 1.0 
rs2306374 3q22.3 MRAS C 0.0012 0.5 1.04 0.2 -0.0005 0.9 
rs17609940 6p21.31 ANKS1A G -0.0004 0.8 1 0.9 -0.0135 0.1 
rs12190287 6q23.2 TCF21 C 0.0006 0.7 1.04 0.1 0.0072 0.3 
rs12526453 6p24.1 PHACTR1 C -0.0017 0.2 1.02 0.4 -0.0010 0.9 
rs3798220 6q25.3 LPA C n/a n/a n/a n/a n/a n/a 
rs11556924 7q32.2 ZC3HC1 C 0.0003 0.8 1.06 0.01 0.0114 0.07 
rs4977574 9p21.3 
CDKN2A/B, 
ANRIL 
G 
-0.0006 0.7 1.06 0.003 0.0025 0.6 
rs579459 9q34.2 ABO C -0.0006 0.8 1.01 0.7 0.0089 0.2 
rs1746048 10q11.21 CXCL12 C -0.0013 0.5 0.98 0.5 0.0117 0.2 
rs12413409 10q24.32 
CYP17A1, 
CNNM2, 
NT5C2 
G 
0.0029 0.2 1.03 0.4 0.0119 0.2 
rs964184 11q23.3 
ZNF259, 
APOA5-A4-
C3-A1 
G 
0.0032 0.1 1.05 0.1 0.0099 0.2 
rs3184504 12q24.12 SH2B3 T -0.0008 0.6 1 0.9 0.0056 0.3 
rs4773144 13q34 
COL4A1, 
COL4A2 
G 
-0.0036 0.02 1.01 0.8 -0.0046 0.4 
rs2895811 14q32.2 HHIPL1 C 0.0021 0.2 1.03 0.2 0.0073 0.2 
rs3825807 15q25.1 ADAMTS7 A 0.0036 0.01 1.04 0.1 0.0065 0.2 
rs12936587 17p11.2 
RASD1, 
SMCR3, 
PEMT 
G 
0.0001 1.0 0.98 0.3 -0.0029 0.6 
rs216172 17p13.3 SMG6, SRR C -0.0004 0.8 0.97 0.3 -0.0090 0.3 
rs46522 17q21.32 
UBE2Z, 
GIP, 
ATP5G1, 
SNF8 
T 
0.0003 0.8 0.98 0.3 -0.0026 0.6 
rs1122608 19p13.2 LDLR G 0.0049 0.003 1.09 0.0008 0.0084 0.2 
rs9982601 21q22.11 MRPS6 T -0.0038 0.07 0.96 0.2 -0.0119 0.1 
 
Table shows results from the discovery meta-analysis for SNPs reported to be associated to coronary artery disease; 
effect estimates (β, or OR) from the meta-analysis are presented in terms of the literature risk allele; “n/a” indicates 
that rs17465637 (MIA3) and rs3798220 (LPA) were not available in our discovery meta-analysis.
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Supplementary Table 7: Association of APOE e4 allele and rs445925 with common cIMT 
 
Study Model SNP β  SE p-value 
AGES 1 APOE4 −0.0018 0.0047 0.7 
 2 APOE4, adjusted for rs445925 −0.0004 0.0048 0.9 
  rs445925 (A), adjusted for APOE4 −0.0128 0.0060 0.03 
CHS 1 APOE4 0.0015 0.0066 0.8 
 2 APOE4, adjusted for rs445925 0.0032 0.0066 0.6 
  rs445925 (A), adjusted for APOE4 −0.0211 0.0082 0.01 
FHS 1 APOE4 −0.0002 0.0071 0.98 
 2 APOE4, adjusted for rs445925 −0.0001 0.0071 0.99 
  rs445925 (A), adjusted for APOE4 −0.0103  0.0135 0.4433 
RS-I 1 APOE4 0.0050 0.0050 0.3 
 2 APOE4, adjusted for rs445925 0.0060 0.0050 0.3 
  rs445925 (A), adjusted for APOE4 −0.0230 0.0060 0.0001 
 
Model #1 included the number of copies of the APOE4 allele as a predictor of ln(common cIMT); Model #2 
included both the APOE4 allele as well as a term for the rs445925 SNP. Models were adjusted for the same 
parameters that were included in the common cIMT GWAS.  
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Supplementary Note 
Section 1A: Study descriptions, discovery phase 
Our analyses were performed within the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) consortium,22 which includes five large population-based prospective cohort studies: the Aging 
Gene-Environment Susceptibility-Reykjavik Study (AGES), the Atherosclerosis Risk in Communities (ARIC) 
Study, the Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS), and the Rotterdam Study I 
(RS-I).  
 
Four additional community-based studies – the Old Order Amish (Amish) Study, the Erasmus Ruchpen Family 
(ERF) Study, the SardiNIA Study, and the Study of Health in Pomerania (SHIP) – collaborated with CHARGE 
for these analyses. For all studies participating in the meta-analyses, each participant provided written 
informed consent and the Institutional Review Board at the parent institution for each respective study 
approved the study protocols. 
 
The studies contributing to this meta-analysis have been described in detail elsewhere. A brief overview 
follows. 
 
The Aging Gene-Environment Susceptibility-Reykjavik Study (AGES):  
The Reykjavik Study cohort originally comprised a random sample of 30,795 men and women born 
in 1907–1935 and living in Reykjavik in 1967. 23 A total of 19381 attended, resulting in 71% 
recruitment rate. The study sample was divided into six groups by birth year and birth date within 
month. One group was designated for longitudinal follow-up and was examined in all stages. One 
group was designated a control group and was not included in examinations until 1991. Other 
groups were invited to participate in specific stages of the study. Between 2002 and 2006, the 
AGES-Reykjavik study re-examined 5764 survivors of the original cohort who had participated 
before in the Reykjavik Study.  
The AGES Reykjavik Study GWAS was approved by the National Bioethics Committee (00-063-
V8+1) and the Data Protection Authority. DNA was genotyped using the Illumina 370CNV 
BeadChip array on 3,664 participants.  Samples were excluded from the dataset based on sample 
failure, genotype mismatch with reference panel, and sex mismatch, resulting in clean genotype 
data on 3,219 individuals. Standard protocols for working with Illumina data were followed, with 
clustering score greater than 0.4.   Prior to genotype imputation, SNPs were excluded using filters 
based on call rate (<97%), Hardy-Weinberg Equilibrium (< 1×10-6), mishap (<1×10-9), and 
mismatched positions between Illumina, dbSNP and/or HapMap resulting in 325,094 SNPs 
passing all QC (of 353,202 prior to cleaning steps).  Imputation was done using MaCH against all 
the HapMap CEPH haplotypes (release 22/NCBI build 36) resulting in 2,533,153 total SNPs for 
analysis.  Association analysis was conducted against all genotypes, and includes the most likely 
imputed gentoypes. 
 
The Old Order Amish Study (Amish):  
The Old Order Amish individuals included in this study were participants of several ongoing 
studies of cardiovascular health carried out at the University of Maryland. 24  Participants were 
relatively healthy volunteers from the Old Order Amish community of Lancaster County, PA. and 
their family members. Examinations were conducted at the Amish Research Clinic in Strasburg, 
PA.  All protocols were approved by the Institutional Review Board at the University of Maryland 
and informed consent was obtained, including permission to use their DNA for genetic studies.   
Genotyping was performed using the Affymetrix GeneChip® Human Mapping 500K Array set. 
Genotype calls were made using the BRLMM genotype calling algorithm. A total of 364,336 
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informative autosomal SNPs that passed our quality-control were included in the analysis. MaCH 
was used for imputation after applying the following filters: 1) not in HapMap; 2) frequency < 0.01; 
3) Hardy-Weinberg p-value < 1 x 10-6; 4) missingness > 0.05. 
 
The Atherosclerosis Risk in Communities Study (ARIC): 
The ARIC study is a multi-center prospective investigation of atherosclerotic disease in a 
predominantly bi-racial population25. Men and women aged 45-64 years at baseline were recruited 
from 4 communities:  Forsyth County, North Carolina; Jackson, Mississippi; suburban areas of 
Minneapolis, Minnesota; and Washington County, Maryland.  A total of 15,792 individuals 
participated in the baseline examination in 1987-1989, with follow-up examinations in 
approximate 3-year intervals, during 1990-1992, 1993-1995, and 1996-1998.   
ARIC Study samples were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0 
(Santa Clara, California); for the current analysis only white participants were analyzed. Sample 
exclusion criteria included discordant with previous genotype data (n=83), genotypic and 
phenotypic sex mismatch (n=32), suspected first-degree relative of an included individual based on 
genotype data (n=297), genetic outlier as assessed by Identity by State (IBS) using PLINK 26 and 
>8 SD along any of the first 10 principal components in EIGENSTRAT 27  with 5 iterations (n=322). 
Autosomal SNPs were used for imputation after exclusion of SNPs with HWE deviation < 5 x 10-5, 
call rate < 95%, or MAF< 1%.   
The Cardiovascular Health Study (CHS): 
The CHS is a population-based cohort study of risk factors for CHD and stroke in adults ≥65 years 
conducted across four field centers in the United States. 28 The original predominantly Caucasian 
cohort of 5201 persons was recruited in 1989-1990 from a random sample of people on Medicare 
eligibility lists and an additional 687 African-Americans were enrolled subsequently for a total 
sample of 5888. 
 
DNA was extracted from blood samples drawn on all participants who consented to genetic testing 
at their baseline examination in 1989-90.   In 2007-2008, genotyping was performed at the 
General Clinical Research Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai using the 
Illumina 370CNV Duo® BeadChip system on the 3980 CHS participants who were free of CVD at 
baseline. Genotyping was successful in 3869 of 3980 persons. QC criteria used to define 
unsuccessful genotyping were a call rate < 95%, sex mismatch, or other sample failures. From a 
total of 335,887 genotyped autosomal SNPs, 306,655 SNPs that were present on HapMap and that 
passed quality control measures (HWE p>10-5, callrate > 0.97, < 3 replicate errors or Mendelian 
inconsistencies among reference CEPH trios) were used for imputation with BIMBAM version 
0.99. 29 Because the other cohorts were predominantly of European ancestry, the African-American 
participants were excluded from this analysis to limit the potential for false positive associations 
due to population stratification, leaving 3,261 participants with an IMT measurement for analysis.  
The Erasmus Rucphen Family Study (ERF): 
The Erasmus Rucphen Family (ERF) Study is comprised of a family-based cohort embedded in the 
Genetic Research in Isolated Populations (GRIP) program in the southwest of the Netherlands. 30 
The aim of this program is to identify genetic risk factors for the development of complex disorders.  
In ERF, twenty-two families that had a minimum of five children baptized in the community 
church between 1850 and 1900 were identified with the help of detailed genealogical records. All 
living descendants of these couples, and their spouses, were invited to take part in the study. 
Comprehensive interviews, questionnaires, and examinations were completed at a research center 
in the area; approximately 3,200 individuals participated.  The examination included the 
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determination of carotid intima media thickness and plaque scores via ultrasonography.  Data 
collection started in June 2002 and was completed in February 2005.  
In the current analyses, 2155 participants for whom phenotypic, genotypic and genealogical 
information was available were studied. 
The Framingham Heart Study (FHS): 
The methods of recruitment and data collection have been described previously for the original 
Framingham Heart Study cohort  (5,209 participants ascertained systematically from two-thirds of 
the households in the town of Framingham, MA, beginning in 1948),31 the Framingham Heart 
Study Offspring cohort (5,124 children of the original cohort, and spouses of those children, 
beginning in 197232 and the Third Generation cohort (4,095 children of the Offspring cohort, 
beginning in 2002).33 The current study was conducted in 3,022 participants of the Offspring 
cohort participating in examination 6 from 1995 to 1998, who underwent contemporaneous carotid 
ultrasonography examination. 
Genotyping was conducted for the SNP Health Association Resource (SHARe) project 
(http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007.v10.p5) 
using the Affymetrix 500K mapping array (250K Nsp and 250K Sty arrays) and the Affymetrix 50K 
supplemental gene focused array on a total of 9,274 individuals from all three cohorts.  To evaluate 
population substratification, we conducted principal component analyses using EIGENSTRAT 27on 
the genotypes from 882 unrelated participants. We estimated the first 10 principal components 
and applied the loadings of these components to all genotyped participants.  Finally, we evaluated 
whether any of these principal components were associated with carotid artery phenotypes.  When 
one of the ten principal components was association with a trait, we adjust for that principal 
component in linear regression models. Genotyping resulted in 503,551 SNPs with successful call 
rate >95% and HWE P>1×10-6 in 8,481 individuals with call rate >97%. Imputation of 2,543,887 
autosomal SNPs in HapMap release 22, build 36, CEU sample was conducted using the algorithm 
implemented in MaCH (version 1.0.15). From a total of 534,982 genotyped autosomal SNPs in 
Framingham, 378,163 SNPs were used in imputation after filtering out 15,586 SNPs (HWE P<1×10-
6), 64,511 SNPs (missingness >0.03), 45,361 SNPs (mishap P<1×10-9), 4,857 SNPs (>100 
Mendelian errors), 67,269 SNPs (frequency <0.01), 2 SNPs (due to strand issues upon merging 
data with HapMap), and a further 13,394 SNPs that were not present on HapMap. We used 200 
biologically unrelated participants to estimate the parameters of the imputation model and 
subsequently applied the estimated parameters to obtain imputed SNPs for all 8,481 participants. 
The Framingham Heart Study was approved by the institutional review boards of Boston 
University and the National Institutes of Health.  All participants provided written informed 
consent. 
Rotterdam Study I and Rotterdam Study II (RS I and RS II): 
The Rotterdam Study is a prospective population-based cohort study to investigate the 
determinants of chronic diseases among participants aged 55 years and older.34 Briefly, residents of 
Ommoord, a district of Rotterdam, in the Netherlands, 55 years of age or older, were asked to 
participate, of whom 7,983 participated (RS I). The baseline examination was conducted in 1990 - 
1993 and consisted of a home interview and research center visit for blood samples. In 1999, 
inhabitants who turned 55 years of age or moved into the study district since the start of the study 
were invited of whom 3011 participated (RS II). The Medical Ethics Committee of Erasmus MC 
approved the study, and all participants gave informed consent. . 
We used the Illumina 550K array to conduct the genotyping. Individuals were excluded for the following 
reasons: (1) Excess autosomal heterozygosity > 0.336 (~FDR<0.1%), (2) Mismatch between called and 
phenotypic gender, (3) If there were outliers identified by the IBS clustering analysis with >3 standard 
deviations from population mean, or IBS probabilities>97%.The exclusion criteria for SNPs were minor 
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allele frequency ≤1%, Hardy-Weinberg equilibrium (HWE) p<10-5, or SNP call rate ≤90% and resulted 
in data on 530,683 SNPs in RS I and 495,478 SNPs in RS II. To obtain imputed data more restrictive 
SNP filters including a minor allele frequency >0.01, SNP Call Rate >0.98, and HWE P>1.0x10-6 were 
applied. Imputation was done with reference to HapMap release 22 CEU using the maximum likelihood 
method implemented in MaCH(version 1.0.15). The final population for the analysis comprised 5,974 
individuals in RS I and 2157 individuals in RS II. Of these, 4699 subjects from RS I and 1980 subjects 
from RS II had IMT measurements available. The analysis was preformed using ProbABEL (version 1.1) 
(http://mga.bionet.nsc.ru/~yurii/ABEL/). 
 
The SardiNIA Study (SardiNIA): 
The SardiNIA Study was conceived as a study of a Sardinian founder population investigating the 
genetics of complex traits/phenotypes, including CV risk factors and arterial properties.35 Over a 3 
year period, 6,148 subjects were enrolled, comprising over 60% of those aged 14-102 in a cluster of 
4 towns. Each subject came to the clinic before breakfast, signed consent forms, and gave a sample 
of fasting blood so that all tests would be uninfluenced by meals at different times. Each subject 
underwent a detailed medical history and full medical examination, blood pressure and 
anthropometric measurements, a 12-lead resting EKG, measurements of arterial structure and 
function, and  personality testing. 
 
A total of 4,305 related individuals participating the Study were genotyped. Genotyped individuals 
had four Sardinian grandparents and were selected for genotyping without regard to their 
phenotypic values. Relationships between genotyped individuals were verified using RELPAIR. 36 
Among the individuals examined, 1,412 were genotyped with the Affymetrix Mapping 500K Array 
Set allowing measurement and not imputation of alleles at the level of each examined SNP. We 
used the SNPs that passed quality control filters evaluating data completeness (>90%), Mendelian 
transmission (<3 inconsistencies), and Hardy-Weinberg equilibrium (p > 1×10-6) to estimate 
genotypes for all the polymorphic SNPs genotyped by the HapMap consortium. The remaining 
individuals (among the set of 4,305 analyzed individuals) were related to this core set of 1,412 
individuals and were genotyped with the Affymetrix 10K genotyping arrays. Genotypes for these 
individuals were imputed using knowledge of IBD sharing with close relatives who were more 
densely genotyped. 37 
The Study of Health in Pomerania (SHIP):  
The Study of Health in Pomerania (SHIP) is a cross-sectional survey in West Pomerania, the north-
east area of Germany. 38 A sample from the population aged 20 to 79 years was drawn from 
population registries. First, the three cities of the region (with 17,076 to 65,977 inhabitants) and the 
12 towns (with 1,516 to 3,044 inhabitants) were selected, and then 17 out of 97 smaller towns (with 
less than 1,500 inhabitants), were drawn at random. Second, from each of the selected 
communities, subjects were drawn at random, proportional to the population size of each 
community and stratified by age and gender. Only individuals with German citizenship and main 
residency in the study area were included. Finally, 7,008 subjects were sampled, with 292 persons 
of each gender in each of the twelve five-year age strata. In order to minimize drop-outs by 
migration or death, subjects were selected in two waves. The net sample (without migrated or 
deceased persons) comprised 6,267 eligible subjects. Selected persons received a maximum of 
three written invitations. In case of non-response, letters were followed by a phone call or by home 
visits if contact by phone was not possible. The SHIP population finally comprised 4,310 
participants (corresponding to a final response of 68.8%). The carotid arteries were assessed with 
ultrasonography in participants at age 45 or older. Data on IMT and carotid plaques are available 
in 2,438 participants, of which 2,321 consented to take part in genome-wide association studies.  
The SHIP samples were genotyped using the Affymetrix Human SNP Array 6.0. Hybridisation of 
genomic DNA was done in accordance with the manufacturer’s standard recommendations. The 
genetic data analysis workflow was created using the Software InforSense. Genetic data were stored 
using the database Caché (InterSystems). Genotypes were determined using the Birdseed2 
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clustering algorithm. For quality control purposes, several control samples where added. On the 
chip level, only subjects with a genotyping rate on QC probesets (QC callrate) of at least 86% were 
included. The overall genotyping efficiency of the GWA was 98.55 % with a minimum sample 
callrate of 92%. Imputation of genotypes in SHIP was performed with the software IMPUTE v0.5.0 
based on HapMap II CEU dataset. 
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Section 1B: Study descriptions, second stage 
 
Austrian Stroke Prevention Study (ASPS): 
The ASPS study is a single center prospective follow-up study on the effects of vascular risk factors 
on brain structure and function in the normal elderly population of the city of Graz, Austria. The 
procedure of recruitment and diagnostic work-up of study participants has been described 
previously. 39 A total of 2007 participants were randomly selected from the official community 
register stratified by gender and 5 year age groups. All participants were Caucasian and had no 
history of neuropsychiatric disease, including previous stroke, transient ischemic attacks, and 
dementia. All had a normal neurologic examination. During 2 study periods between September 
1991 and March 1994 and between January 1999 and December 2003 an extended diagnostic 
work-up including Duplex scanning of extracranial arteries, brain MRI and neuropsychological 
testing was done in 1076 individuals aged 45 to 85 years randomly selected from the entire cohort. 
In all participants who gave informed consent blood was drawn for DNA extraction since 1992. 
Genotyping was performed in 996 participants at the Human Genotyping Facility, Genetic 
Laboratory Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands using the 
Illumina Human610-Quad BeadChip® system. QC criteria used to define unsuccessful genotyping 
were a call rate < 97%, sex mismatch, or other sample failures. SNPs that were present on HapMap 
and that passed quality control measures (HWE p>1×10-5, callrate > 0.97, < 3 replicate errors or 
Mendelian inconsistencies among reference CEPH trios) were used for imputation to plus strand of 
NCBI build 36, HapMap release #22.   
 
Carotid Atherosclerosis Progression Study (CAPS): 
The Carotid atherosclerosis progression study (CAPS) is a community-based study from Germany. 
Details of the study have been published before. 40 In brief, members of a German primary health 
care service population (n=32708) were invited to participate. Within a predefined time limit 6962 
(21.3%) agreed to participate. Of these, 5,056 were invited to follow-up examination after three 
years and 3383 (67%) participated. 1,000 individuals in whom carotid IMT measurements were 
performed, and in whom there was sufficient DNA for investigation, were genotyped and data on 
these individuals contributed to this study. Informed written consent was obtained from all 
participants, and the study protocol was approved by the local ethical committee. 
Genotyping was performed at Helmholtz Zentrum Munich, Germany in 2009 using the Affymetrix 
6.0 chip.   From a total of 906,716 genotyped autosomal SNPs, 756,948 passed the quality control 
measures (no-call rate < 10%, MAF > 0.01). We flagged SNPs for HWE but we have not removed 
them from the analysis. From the total of 993 samples, 967 samples passed the quality control 
measurements (no-call rate > 10%, cryptic relatedness and outliers in the multidimensional 
samples were removed). We used the software BEAGLE 41 for the imputation of ungenotyped SNPs. 
We removed imputed SNPs with MAF < 0.01 or with posterior probability < 0.9, resuling in 
1,458,429 additional SNPs that were used in the analysis. Linear regression was performed on the 
resulting data; the inflation factor was 1. 
 
Gutenberg Heart Study (GHS): 
The GHS is designed as a population-based, prospective, observational single-center cohort study 
in the Rhein-Main-Region in western Mid-Germany. The primary aim of GHS is to evaluate and 
improve cardiovascular risk stratification.  
The sample was drawn randomly from the governmental local registry offices in the city of Mainz 
and the district of Mainz-Bingen (In Germany, there is a legal obligation to register; therefore these 
registry offices contain all citizens of the defined area.) The sample was stratified 1:1 for gender and 
residence (urban and rural), and in equal strata for decades of age. Individuals between 35 and 74 
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years of age were enrolled and a written informed consent was obtained from all participants. 
Exclusion criteria were insufficient knowledge of the German language, and physical or 
psychological inability to participate in the examinations at the study center. The study protocol 
and the sampling design were approved by the local ethics committee, and by the local and federal 
data safety commissioners. 
DNA was examined from blood samples of the first 3500 participants who consented to genetic 
testing at their baseline examination in 2007-08. Genomic DNA was isolated from buffy-coats of 
EDTA-Plasma samples using the method of Miller et al., (1988). For GWA, genotyping was 
conducted on the Affymetrix Genome-Wide Human SNP 6.0 Array. Processing of DNA samples 
using the Affymetrix Genome-Wide Human SNP Nsp/Sty Assay 5.0 and hybridization was done in 
accordance with the manufactures’ standard recommendations. Genotyping was successful in 3196 
persons. 
Genotyping was performed using Birdseed as implemented in the Affymetrix Power Tools v1.08. 
Samples with a call rate < 97%, deviations in expected heterozygosity and doubtful identical by 
state patterns were excluded from the analysis. On the marker level, SNPs were removed with a call 
rate < 2%, a minor allele frequency < 1%, or a p-value < 0.0001 in the asymptotic test for deviation 
from Hardy-Weinberg-Equilibrium. Imputation was carried out with IMPUTE v0.5. 
 
MONICA/KORA Augsburg Study (KORA): 
The MONICA/KORA Augsburg Study consisted of a series of independent population-based 
epidemiological surveys of participants living in the region of Augsburg, Southern Germany. All 
survey participants are residents of German nationality identified through the registration office. 
The presented data were derived from the fourth population-based Monitoring of Trends and 
Determinants in Cardiovascular Disease (MONICA)/ Cooperative Health Research in the Region of 
Augsburg (KORA) survey S4. This cross-sectional survey covering the city of Augsburg (Germany) 
and two adjacent counties was conducted in 1999/2001 with 4,261 individuals aged 25 to 74 years. 
In a follow-up examination conducted in 2006/08 (MONICA/KORA F4), a number of 3,080 
subjects participated. All participants underwent standardized examinations including blood 
withdrawals for plasma and DNA. For the MONICA/KORA genome-wide association study, a 
number of 1,814 subjects were selected from F4 samples. After excluding subjects with no IMT 
measurements available, the final population for the MONICA/KORA data comprised 1,593 
subjects.   
Genotyping for F4 was performed using Affymetrix Human SNP Array 6.0. Hybridisation of 
genomic DNA was done in accordance with the manufacturer’s standard recommendations. 
Genotypes were determined using Birdseed2 clustering algorithm. For quality control purposes, we 
applied a positive control and a negative control DNA every 96 samples. On chip level only subjects 
with overall genotyping efficiencies of at least 93% were included. In addition the called gender had 
to agree with the gender in the MONICA/KORA study database. Imputation of genotypes was 
performed using maximum likelihood method with the software MaCH v1.0.9. 
 
The Orkney Complex Disease Study (ORCADES): 
The Orkney Complex Disease Study (ORCADES) is an ongoing family-based, cross-sectional study 
in the isolated Scottish archipelago of Orkney. Genetic diversity in this population is decreased 
compared to Mainland Scotland, consistent with the high levels of endogamy historically.  Data for 
participants from a subgroup of ten islands were used for this analysis. Fasting blood samples were 
collected and over 200 health-related phenotypes and environmental exposures were measured in 
each individual. All participants gave informed consent and the study was approved by Research 
Ethics Committees in Orkney and Aberdeen. 
We genotyped 318,237 SNPs for each individual using the Illumina HumanHap300 beadchip. 
Alleles were called in BeadStudio using Illumina cluster files. Subjects were excluded if they 
fulfilled any of the following criteria: genotypic call rate <98%, mismatch between reported and 
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genotypic sex, unexpectedly low genomic sharing with first degree relatives, excess autosomal 
heterozygosity, or outliers identified by IBS clustering analysis. We excluded SNPs on the basis of 
minor allele frequency (<0.02), HWE (P<1×10-10), call rate (<98%). Pregnant women were 
excluded from the study. MaCH v1.0.15 was used to impute over 2 million autosomal SNPs from 
HapMap build 36. Analysis was performed using ProbABEL to account for the probabilistic nature 
of imputed genotype calls and kinship accounted for using a mixed polygenic model (mmscore or 
FASTA routine). 
 
The Cardiovascular Risk In Young Finns (YFS) study: 
The Cardiovascular Risk in Young Finns (YFS) is a population-based 27 year follow up-study  
(http://med.utu.fi/cardio/youngfinnsstudy/). The first cross-sectional survey was conducted in 
1980, when 3,596 Caucasian subjects aged 3-18 years participated. In adulthood, the latest 27-year 
follow-up study was conducted in 2007 (ages 30-45 years) with 2,204 participants. The study 
cohort for the present analysis comprised subjects who had participated in the ultrasound study in 
2007 and had other risk factor data. 42 
DNA was extracted from blood samples drawn on all participants in 2001 and 2007. In 2009 
genotyping was performed at the Sanger institute (UK) using the custom-built Illumina BeadChip 
Human670K from 2442 YFS participants (1123 males, 1319 females) including 546677 SNPs. 
Genotypes were called using Illumina’s clustering algorithm. (Teo et al, A genotype calling 
algorithm for the Illumina BeadArray platform, Bioinformatics. 2007 October 15; 23(20): 2741–
2746) In the start of QC protocol we had 2556 samples in YF intensity file, after initial clustering we 
removed 2 subjects (CR<0.90), thus the main clustering include 2554 subjects, from these 54 
samples failed QC. Thus genotyping pipeline contained 2500 subject s from these 54 were removed 
due to Sanger genotyping pipeline QC criteria (i.e., duplicated samples, heterozygosity, low call 
rate, or Sequenom fingerprint discrepancy). After genotyping pipeline QC the following filters were 
applied to the remaining data: MAF 0.01, GENO 0.05, MIND 0.05, and HWE 1×10-6. 3 of 2500 
individuals were removed for low genotyping (MIND > 0.05), 11766 markers were excluded based 
on HWE test ( p ≤ 1×10-6), 7,746 SNPs failed missingness test (GENO > 0.05), 34596 SNPs failed 
frequency test (MAF < 0.01 ) and one individual failed gender check. None were removed by 
subsequent heterozygosity check. New binary files were created after removing the individual 
which failed the gender-check and identity-by-descent (IBD) matrix was subsequently calculated in 
PLINK 26. There were 546,770 SNPs and 2,496 individuals at this point which were utilized to 
generate the genome file. There were 51 pairs of individuals with pi-hat greater than 0.2 thus these 
individuals removed due to possible relatedness. One of the pair was removed using greater 
missingness as criteria. After final frequency and genotyping running, there was 546,677 SNPs 
available from sample of 2,442 YFS subjects. From these a total of 546,677 genotyped autosomal 
SNPs, those SNPs that were present on HapMap and that passed quality control measures were 
used for imputation with MaCH version 1.0 (http://www.sph.umich.edu/csg/abecasis/MaCH/). 
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Section 1C: Associations with coronary artery disease, CARDIoGRAM 
Consortium 
The CARDIoGRAM Consortium represents a GWAS meta-analysis of coronary artery disease (CAD) 
comprising a discovery set of 22,233 individuals with CAD (cases) and 64,762 controls and a 
replication stage of 56,682 additional individuals. The methods of consortium organization, 
genotyping, imputation, and analysis have been described previously. 43 In brief, the consortium used 
log-additive models adjusting for age (at first event onset for cases or recruitment for controls) and 
gender and taking into account the uncertainty of possibly imputed genotypes using logistic regression. 
The primary results and replication are described in recent Nature Genetics manuscript 44. For the 
lookup of SNPs from our analyses of common cIMT and plaque, we examined results from the 
consortium’s default meta-analysis, a fixed effect model with inverse variance weighting no indication 
for heterogeneity for a SNP (P for Q > 0.01). 
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Section 2A: Participant characteristics, discovery phase 
Characteristic  AGES 
N=3073 
Amish 
N=1,054 
ARIC 
N= 7,767 
CHS 
N= 3,261  
ERF 
N= 1,809  
FHS 
N=3,004 
RS I 
N= 4,699  
SardiNIA 
N=4,235 
SHIP 
N= 2,309 
Age, years  76.4 (5.4) 48.1 (15.9) 54.3 (5.7) 72.3 (5.4) 48.5 (14.5) 58.5 (9.7) 68.9 (8.70) 43.5 (17.5) 61.8 (9.5) 
Women, %  57.7% 49.4% 53% 61% 56.5 53.3% 59.3% 56.2% 48.6% 
Hypertension, %  80.6% 9.3% 27% 51% 51.4% 40.5% 55.9% 29.1% 72.4% 
Diabetes, %  11.6% 2.1% 8% 12% 6.1% 8.6% 10% 4.8% 10.1% 
Current smoker, %  12.6% 9.4% ** 25% 11% 39.4% 15.6% 23.4% 20.2% 19.2% 
Total cholesterol, 
mg/dL  
217.9  
(44.5) 
211.3  
(48.1) 
214.7 
(40.5) 
213.0 
(38.9) 
214.4  
(42.6) 
205.9  
(39.7) 
256.0   
(46.8) 
208.6  
(42.1) 
234.3 
(47.9) 
HDL cholesterol, 
mg/dL  
61.0  
(17.1) 
55.7  
(14.8) 
50.7  
(16.8) 
55.3  
(15.8) 
49.5  
(14.1) 
51.1  
(16.1) 
51.8  
(13.9) 
64.4  
(14.9) 
55.3  
(17.8) 
Triglyceride, mg/dL  107.0  
(59.0) 
74.9  
(47.1) 
136.0 
(89.5) 
140.4 
(76.4) 
118.6 
 (68.1) 
142.3  
(138.6) 
N/A 87.2  
(61.4) 
177.6 
(134.8) 
BMI, kg/m2  27.1 (4.5) 26.9 (4.7) 26.9 (4.7) 26.3 (4.5) 26.80 (4.7) 27.9 (5.1) 26.3 (3.7) 25.3 (4.7) 28.5 (4.6) 
Prevalent CVD, %  21.9% 6.9% 5% 0%* 3.1% *** 10.4% 30.8% 1.7% 8.4% 
IMT common carotid  0.97 (0.1) 0.74 (0.2) 0.77 (0.2) 1.03 (0.2) 0.82 (0.2) 0.74 (0.2) 1.02 (0.2) 0.54 (0.1) 0.93 (0.2) 
IMT internal carotid  n/a n/a 0.86 (0.48) 
N=4906 
1.23 (0.53) 
N=3260 
n/a 0.79 (0.52) 
N=2796 
n/a n/a n/a 
Plaque/stenosis 
present, %  
66.9% 
N=3,073 
n/a 18% 
N=7,957 
66.0% 
N=3,138 
66.4% 
N=1,945 
17.7% 
N=3,019 
61% 
N=3,752 
n/a 70.1% 
N=2,321 
Numbers in table are Mean (SD) or percentage. N in the column headers indicates the number of participants with common carotid IMT available. BMI=body mass index; 
HDL=high density lipoprotein. Diabetes was defined as fasting blood glucose > 125 mg/dL, a random blood glucose of  > 200 mg/dL, or use of insulin or oral hypoglycemic 
agents; hypertension was defined as blood pressure >140/90 mmHg or on anti-hypertensive medication; current cigarette smoking was defined as self-reported cigarette smoking 
of at least 1 cigarette per day for a year at any attended exam; cardiovascular disease was defined as coronary heart disease, stroke or transient ischemic attack, or congestive heart 
failure.  
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Section 2B: Participant characteristics, second stage 
Characteristic  ASPS 
N=837 
ORCADES 
N=687 
CAPS 
N= 967 
GHS 
N=3,194 
KORA 
N=1,593 
RS II 
N=1,980 
YFS 
N=1,982 
Age, years  65.2 (8.0) 53.6 (15.3) 48.7 (13.2) 55.9 (10.9) 60.4 (9.0) 64.7 (7.9) 37.7 (5.0) 
Women, %  57% 53% 50.5% 48.8% 51% 54.4% 55% 
Hypertension, %  72.5% 21% 21.7% 53.0% 45% 60.3% 6% 
Diabetes, %  10% 2% 3.1% 7.4% 8% 10.6% 2.2% 
Current smoker, %  11.4% 8% 15.3% 18.3% 14% 19.6% 18% 
Total cholesterol, mg/dL  262.5 (45.9) 224.7 (45.2) 215.0 (39.9) 224.2 (41.4) 222.1 (39.0) 223.6 (38.3) 194.3 (34.8) 
HDL cholesterol, mg/dL  56.2 (17.2) 65.0 (15.5) n/a 56.9 (16.1) 56.8 (14.6) 53.1 (14.2) 51.8 (12.8) 
Triglyceride, mg/dL  133.1 (74.4) 117.8 (58.5) n/a 126.1 (74.9) 132.5 (94.5) 141.4 (77.7) 122.6 (80.5) 
BMI, kg/m2  26.7 (6.1) 27.69 (4.8) 26.74 (4.1) 27.2 (4.8) 28.2 (4.8) 27.3 (4.2) 26.0 (4.8) 
Prevalent CVD, %  0% 8% n/a 7.2% 3% 10.6% 
 
0% 
IMT common carotid  n/a 0.57 (0.21) 0.726 
(0.187) 
0.7 (0.1) 0.88 (0.13) 0.99 (0.17) 0.66 (0.10) 
Plaque/stenosis present, 
%  
60.5% 
N=837 
n/a n/a 34.8% 
N=3,161 
n/a n/a 2.4% 
N=2,015 
 
Numbers in table are Mean (SD) or percentage. N in the column headers indicates the number of participants with common carotid IMT available. BMI=body mass index; 
HDL=high density lipoprotein. Diabetes was defined as fasting blood glucose > 125 mg/dL, a random blood glucose of  > 200 mg/dL, or use of insulin or oral hypoglycemic agents; 
hypertension was defined as blood pressure >140/90 mmHg or on anti-hypertensive medication; current cigarette smoking was defined as self-reported cigarette smoking of at 
least 1 cigarette per day for a year at any attended exam; cardiovascular disease was defined as coronary heart disease, stroke or transient ischemic attack, or congestive heart 
failure.   
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Section 3A: Phenotype information, discovery phase 
 
 AGES Amish ARIC CHS ERF FHS RS I SardiNIA SHIP 
Years 
measured 
2002-2006 2003-2008 1987-89 1989-90  
(Baseline)  
 
2002 - 2005 1996-1998 
 (Cycle 6) 
1990-1993 2001-2004 
(Baseline) 
1997-2001 
(Baseline) 
Site 
measured 
(common 
carotid) 
Near & far wall 
Left & right 
Far wall 
Left & right 
Far wall 
Left & right 
 
Near & far wall 
Left & right 
Near & far wall 
Left & right 
Near & far wall 
Left & right 
Near & far wall 
Left & right 
Far wall 
Right 
Far wall 
Left & right 
Device Acuson Sequoia 
C256, system 
5,07 (AS) and GE 
Vivid 7 version 
5.1.1 (GE). 
ATL Phillps HDI 
5000 Ultrasound 
machine. 
Duplex scanner 
(Biosound 2000 
II SA) high 
resolution 7,5-
MHz transducer 
B-mode 
ultrasonography 
(model SSA-270A; 
Toshiba). The 
ultrasound probe 
was a 5.0 MHz 
probe with 
imaging 
characteristics of a 
probe with a 
frequency of 6.7 
MHz.  It was used 
for both the CCA 
and the 
ICA.  Images were 
not gated to either 
systole or diastole 
Duplex scanner 
(ATL UltraMark 
IV, Advanced 
Technology 
Laboratories) 
Duplex scanner 
(Toshiba SSH-
140A with high-
resolution, 7,5-
MHz transducer 
for CCA and a 
5,0-MHz 
transducer for 
the ICA) 
Duplex scanner 
(ATL UltraMark 
IV, Advanced 
Technology 
Laboratories) 
High-resolution B-
mode carotid 
ultrasonography 
was performed by 
use of a linear-
array 5- to  7.5-
MHz transducer 
(HDI 3500- ATL 
Ultramark Inc) 
 
B-Mode 
ultrasonography 
was performed 
using a 5 MHz 
linear array 
transducer with 
an axial 
resolution of less 
than 0.5mm and 
a high resolution 
instrument 
(Diasonics VST 
Gateway, Santa 
Clara, California, 
USA). 
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Section 3B: Phenotype information, second stage 
 
 
 
 ASPS CAPS GHS KORA ORCADES RS II YFS 
YEARS measured 1991-1994 and 
1999-2003 
(Baseline) 
Baseline Baseline Baseline  
(2006-08) 
2005-2007 2000-2001 2007 
Site measured 
(for common 
carotid IMT) 
n/a Far wall 
Left & right 
Far wall 
Left & right 
Far wall 
Left & right 
Far wall 
Right 
Near & far wall 
Left & right 
Far wall 
Left 
Device Color-coded 
B-mode 
Duplex-
scanning 
(Diasonics, 
VingMed 
CFM 750) 
7.5-10.0 MHz 
linear array 
transducer 
(P700SE, 
Phillips 
Medical 
System) 
ie33 Ultrasound 
System 
(Philips, The 
Netherlands) 
11 to 3 MHz 
linear array 
transducer 
B-Mode 
Ultrasonography 
B-mode 
ultrasound 
sonography 
(Sonoline G, 
Siemens 
Medical 
Solutions, 
Munich, 
Germany) 
Sonosite Titan 
B mode ultra-
sonography 
Duplex scanner 
(ATL 
UltraMark IV, 
Advanced 
Technology 
Laboratories) 
Sequoia 512 
ultrasound 
mainframe 
(Acuson, CA, 
USA), 13.0 MHz 
linear array 
transducer 
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Section 4A: Methods for characterization of IMT and plaque, discovery phase 
 
AGES:  
Carotid artery intima-media thickness was measured with standardized longitudinal B-mode 
images from the near and far wall of the common carotid artery for a predefined 10mm segment at 
defined interrogation angles. Standard images were obtained from 4 angles at each site. The 
average of all these CIMT values comprises the CIMT outcome parameter. 
The presence of atherosclerotic lesions was quantified during the ultrasound examination of the 
left and right carotid bifurcation and internal carotid artery. The most severe lesion per segment 
was assessed in a semi-quantitative manner as none, minimal, moderate or severe lesion. Also, an 
image was stored of the observed plaques. 
Amish: 
A longitudinal view of the common carotid artery was obtained and the far wall IMT was analyzed 
using a semi-automated edge detector system over a 1 cm distance.  The maximum IMT was 
determined.  The mean of four measurements was averaged (two from the left common carotid 
artery and two from the right common carotid artery) from different still frames gated to the ECG. 9  
 
ARIC: 
Carotid artery intima-media thickness measured (bilaterally) with B-mode real-time ultrasound in 
the common (1 cm proximal to the dilatation of the carotid bulb), bifurcation (1 cm proximal to the 
flow divider), and the internal carotid artery (1 cm distal to the flow divider). Standardized 
interrogation angles were used. Data was acquired by trained sonographers at four study sites and 
all images were read centrally. For each arterial segment, 11 IMT measurements (at 1mm 
increments) on the near and far wall were attempted, on average 5 were obtained. 45 For analyses, 
the mean of the maximal far wall IMT were used. 46 
Plaque was defined as the presence of a lesion defined by abnormal arterial wall thickness, shape, 
or texture. Acoustic shadowing was defined as a reduction in amplitude of echoes caused by 
intervening structures with high attenuation. 47 
CHS: 
IMT was characterized with one longitudinal image of the common carotid artery and three 
longitudinal images of the internal carotid artery. The maximal IMT of the common carotid artery 
and of the internal carotid artery was defined as the mean of the maximal IMT of the near and far 
walls on both the left and right sides. 48 
Plaque was defined by the presence of the largest focal lesion classified by surface characteristics, 
echogenicity, and texture. 48 
 
ERF: 
IMT was defined using ultrasonography of the common carotid artery, carotid bifurcation, and 
internal carotid artery of the left and right carotid arteries performed with a 7.5-MHz linear-array 
transducer (ATL UltraMark IV). When an optimal longitudinal image was obtained, it was frozen 
on the R wave of the ECG and stored on videotape. This procedure was repeated three times for 
both sides. The actual measurements of intima-media thickness were performed off-line. The 
interfaces of the distal common carotid artery were marked across a length of 10 mm. The 
beginning of the dilatation of the distal common carotid artery served as a reference point for the 
start of the measurement. The average of the intima-media thickness of each of the three frozen 
images was calculated. For each individual, the common carotid intima-media thickness was 
determined as the average of near- and far-wall measurements of both the left and right arteries.  
The common carotid artery and the carotid bifurcation were evaluated for the presence (yes/no) of 
atherosclerotic lesions on both the near and far walls of the carotid arteries. Plaques were defined 
as a focal widening relative to adjacent segments, with protrusion into the lumen composed either 
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of only calcified deposits or a combination of calcification and noncalcified material. The size or 
extent of the lesions was not quantified. 49 
 
FHS: 
IMT was characterized with 1 longitudinal images of the distal CCA taken at end diastole and 2 
longitudinal views of the ICA at end diastole.  Measurement of the peak systolic velocity in the ICA 
was obtained with color Doppler imaging and duplex ultrasound. 50,51 
Plaque was defined by carotid stenosis of 25% or greater. 51,52  
 
Rotterdam (RS I and RS II): 
IMT for the common carotid artery was characterized using an average of 3 measurements across a 
length of 10 mm with the beginning of the dilatation of the distal CCA as the reference point. 
Average of near- and far- wall measurements of both the left and right arteries were calculated. 
Both mean and the max were computed.  Bifurcation was defined the part of the artery between the 
common carotid artery and the tip of the flow divider. Internal Carotid Artery was defined as the 
part f the artery after the tip of the flow divider. The max IMT at bifurcation and ICA were used. 49 
 
Plaques were defined as a focal widening relative to adjacent segments, with protrusion into the 
lumen composed either of only calcified deposits or a combination of calcification and noncalcified 
material. 53 
 
SardiNIA: 
IMT was characterized while the subject lay in the supine position in a dark, quiet room. The 
stabilized BP after 15 minutes from the onset of testing was used for subsequent analyses. The right 
CCA was examined with the head tilted slightly upward in the midline position. The transducer was 
manipulated so that the near and far walls of the CCA were parallel to the transducer footprint and 
the lumen diameter was maximized in the longitudinal plane. A region 1.5 cm proximal to the 
carotid bifurcation was identified, and the IMT of the far wall was evaluated as the distance 
between the luminal-intimal interface and the medial-adventitial interface. IMT was measured on 
the frozen frame of a suitable longitudinal image with the image magnified to achieve a higher 
resolution of detail. The IMT measurement was obtained from 5 contiguous sites at 1-mm intervals, 
and the average of the 5 measurements was used for analyses. 54,55 
Common carotid artery plaque was defined as focal encroachment of the arterial wall. 
SHIP: 
For the characterization of IMT, both carotid arteries were assessed in B-mode. The maximum far-
wall IMT of the distal straight portion of the right and left common carotid arteries (CCA) 
proximally from the bifurcation was assessed by selecting the highest IMT value of in total 10 
consecutive measurement points (in 1-mm steps) from the bulb. The ‘mean of the maximum IMT’ 
was calculated by averaging the maximum IMT of both, the right and left CCA far wall. IMT 
measurement was performed manually on digitally stored images by trained and certified 
readers.56 
 
Atherosclerotic plaques were defined as a focal thickening of the vessel wall with protrusion into 
the vessel lumen relative to adjacent segments or as a localized roughness with increased 
echogenicity. 
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Section 4B: Methods for characterization of IMT and plaque, second stage 
ASPS:  
For plaque, the largest focal lesion was classified by surface characteristics, echogenicity, and 
texture. 57 
 
CAPS: 
For IMT, one longitudinal image of the common carotid artery was measured using a standard 
protocol as previously published. 40 Images were digitally captured during the systole of a single 
heartbeat and mean IMT determined using semi-automated software with high inter and intra-
observer reproducibility. The mean of left and right CCA-IMT was used in all analyses.  ICA and 
bifurcation IMT was also measured, but only CCA IMT was used in this analysis 
 
GHS:  
IMT was characterized using one image loop from a longitudinal sectional view of the common 
carotid artery. Evaluation was performed by a semi-automatic computerized system (Qlab 
quantification software, IMT; Philips, NL); triggered according to the Q wave of the ECG. IMT 
was recorded over a region of 10mm at a position 1cm proximal to the carotid bulb and without 
plaque. The IMT of the common carotid artery was defined as the mean of the means of all 
automatized measurements of the far walls on both, the left and right side. 
Plaques were defined as thickening of the IMT of at least 1,5mm in any of the arteries (ACC, ACI 
and ACE). The number of plaques from both sides was recorded and subjects being classified as 
plaque positive when at least one plaque was measured on either side. 
 
KORA: 
The mean far-wall IMT was determined using the average of the measurements of frozen images 
from both the left and right CCA to calculate artery thickness of the CCA, 1 cm below the 
bifurcation ((mean left + mean right) /2). 
 
ORCADES: 
For IMT, one longitudinal image of the common carotid artery centered ~2 cm below the 
bifurcation was measured three times using the Sonosite tool. The mean of the three IMT 
readings from the far wall on the right side was taken for analysis. 
YFS: 
For IMT, the left carotid artery was scanned. The image was focused on the posterior (far) wall, 
and images were recorded from the angle showing the greatest distance between the lumen-
intima interface and the media-adventitia interface. A scan including the beginning of the carotid 
bifurcation and the common carotid artery was recorded and stored in digital format on optical 
discs for subsequent off-line analysis. A minimum of four measurements of the common carotid 
far wall were taken 10 mm proximal to the bifurcation to derive mean of the maximal carotid 
IMT. 
The far and near walls of the left common carotid artery and carotid bulb area were scanned for 
the presence of atherosclerotic plaque, defined as a distinct area of the vessel wall protruding into 
the lumen >50% of the adjacent intima–media layer. 
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Section 5A: Analysis logistics, discovery phase 
 AGES  Amish ARIC  CHS  ERF FHS  RS I  SardiNIA SHIP 
Adjustments Age and sex age, age2, 
sex, 
age×sex, & 
age2×sex 
age and field 
center within 
each sex 
age, sex, 
clinic: as 
adjustment in 
genotype-
phenotype 
model  
Age  
(sex adjusted 
in strata, as 
above) 
Age and 
principal 
components 1-
10  
(sex-specific, 
unstandardized 
residuals) 
Age, Sex 
(Sex specific         
unstandardized 
residuals) 
Age, Sex Age, sex 
Analysis 
method 
Linear 
regression 
models for 
quantitative 
traits and 
logistic 
regression for 
qualitative 
traits 
Mixed 
model with 
relationship 
matrix to 
account for 
family 
structure 
Linear 
regression 
models for 
quantitative 
traits and 
logistic 
regression for 
qualitative 
traits 
Linear 
regression 
models for 
quantitative 
traits and 
logistic 
regression for 
qualitative 
traits 
Linear mixed 
models 
Linear mixed 
effect models 
to account for 
family 
structure  
Linear 
regression 
models for 
quantitative 
traits and 
logistic 
regression for 
qualitative 
traits 
Variance 
Component 
Based 
Analysis to 
Account for 
Relatedness37 
Linear 
regression 
models for 
quantitative 
traits and 
logistic 
regression 
for 
qualitative 
traits 
Analysis 
software 
R using 
ProbABEL 
software 
Mixed 
Model 
Analysis for 
Pedigrees 
(MAPP),  
R using 
ProbABEL 
software 
R version 2.7  
 
R, GenABEL, 
ProbABEL 
R version 2.6.1, 
using lmekin  
R using 
ProbABEL 
software 
(version 1.1)  
Merlin SNPTEST 
v1.1.5; 
QUICKTES
T v0.94 
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Section 5B: Analysis logistics, second stage  
 
 ASPS ORCADES CAPS GHS KORA RS II YFS 
Adjustments Age, sex Age, sex, first 
three principal 
components 
Age, sex Age, sex 
 
Age ,sex Age, Sex 
(Sex specific         
unstandardized 
residuals) 
Age, sex 
Analysis 
method 
Logistic 
regression 
Linear 
regression with 
mmscore 
(FASTA) to 
account for 
relatedness 
Linear 
regression 
Linear 
regression 
models for 
quantitative 
traits and 
logistic 
regression for 
qualitative traits 
Linear 
regression 
Linear 
regression 
models for 
quantitative 
traits  
Linear 
regression 
models for 
quantitative 
traits and 
logistic 
regression for 
qualitative traits 
Analysis 
software 
R version 2.10 
 
ProbABEL Plink 
 
SNPTEST MaCH, 
ProbABEL 
R using 
ProbABEL 
software 
(version 1.1) 
ProbABEL 
MAPP, developed by Dr. J. R. O’Connell at UMB (joconnel@medicine.umaryland.edu) 
Plink: http://pngu.mgh.harvard.edu/~purcell/plink/ 
ProbABEL 58: http://mga.bionet.nsc.ru/~yurii/ABEL/ 
QUICKTEST: http://toby.freeshell.org/software/quicktest.shtml 
R: http://www.r-project.org 
SAS: Cary, North Carolina, http://www.sas.com/presscenter/guidelines.html 
R: http://www.r-project.org 
SAS: Cary, North Carolina, http://www.sas.com/presscenter/guidelines.html 
SNPTEST: http://www.stats.ox.ac.uk/~marchini/software/gwas/snptest.html 
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Section 6: Genotyping & quality control, discovery phase  
 
 AGES Amish ARIC ERF CHS FHS RS I SardiNIA SHIP 
Genotyping 
platforms, 
SNP panel 
Illumina 
HumanHap 
370CNV 
Affymetrix 
500K 
Affymetrix 
Genome-Wide 
Human SNP 
Array 6.0  
Version 3 
Illumina 
Infinium II 
HumanHap550  
Illumina 
HumanHap 
370CNV  
Affymetrix 
500K (250K 
Nsp & 250K 
Sty, MIPS 50K  
Version 3 
Illumina 
Infinium II 
HumanHap550  
Affymetrix 
500K 
Affymetrix 
Genome-
Wide Human 
SNP Array 
6.0  
Gentoyping 
center 
NIA/NIH UMB 
Genomic 
Core Facility 
Broad Institute Erasmus MC 
Rotterdam 
Cedars-Sinai, 
Rotter & 
Taylor  
Affymetrix  Erasmus MC 
Rotterdam 
Lanusei, 
Sardinia, Italy 
Affymetrix, 
University of 
Greifswald 
Genotyping 
calling 
algorithm 
Illumina 
BeadStudio 
BRLMM BRLMM Illumina 
BeadStudio 
Illumina 
BeadStudio  
BRLMM  Illumina 
BeadStudio 
BRLMM Birdseed V2 
Call rate 
threshold 
> 95% 95% > 95%  ≥ 98% > 95%  > 97%  > 97.5% 95% > 92% 
Other 
exclusions 
sample 
failures, 
genotyped 
sex different 
from 
recorded 
sex, 
discordance 
with prior 
genotyping 
 Discordant with 
previous 
genotyping, 
genotypic sex 
mismatch, 
suspected 1st 
degree relative 
of included 
individual by 
genotype, 
genetic outlier 
as assessed by 
Plink IBS or 
EIGENSTRAT  
 sample 
failures, 
genotyped 
sex different 
from 
recorded sex, 
discordance 
with prior 
genotyping  
>1000 
Mendelian 
errors  
Heterozygosity 
5 SD from 
mean 
(<25.758% or 
>29.958%) 
 Markers with 
an excess of 
Mendelian 
inconsistencies 
(>2 in 67 trios; 
500K or >4 in 
1266 trios; 10K) 
removed 
15 individuals 
were 
excluded due 
to duplicate 
samples (by 
IBS) or 
reported vs. 
genotyped 
gender 
mismatch 
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Section 6 (continued): Genotyping & quality control, discovery phase  
 
 AGES Amish ARIC ERF CHS FHS RS I SardiNIA SHIP 
Imputation 
software 
Mach  
(version 1.0.16) 
Mach  
(version 
1.0.16) 
Mach  
(version 1.0.16) 
Mach 
(v1.0.1.5) 
BIMBAM  
(v.0.99)  
Mach  
(v1.0.1.5)  
Mach  
(v1.0.1.5)  
Mach  
(v1.0.1.16) 
IMPUTE 
(v0.5.0) 
Imputation: 
reference 
panel 
HapMap CEU,  
build 36 
HapMap 
CEU, build 36 
BRLMM to 
Hapmap-V1 CEU 
backbone (build 
35) 
HapMap 
CEU trios 
(build 36, 
release 22) 
HapMap CEU, 
Build 36  
HapMap 
CEU, Build 
36,  
Release 22 
HapMap CEU 
trios (build 36, 
release 22) 
HapMap CEU 
trios (build 
36, release 
22) 
HapMap CEU 
trios (build 
36, release 
22) 
Pre-
imputation 
MAF filter 
< 0.01 < 0.01 < 0.01 ≤ 0.01 none < 0.01 ≤ 0.01 < 0.05 none 
Pre-
imputation 
HWE filter 
< 1x10-6 < 1x10-6 < 1x10-5 < 1x10-6 < 1x10-5 < 1x10-6 < 1x10-6 < 1x10-6 none 
Pre-
imputation 
call 
frequency 
filter 
< 90% < 95% < 95% ≤ 90% 97%  < 97% ≤ 90%  < 90% < 98.6% 
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Other pre-
imputation 
SNP filters 
SNPs with 
mismatched 
position, and/or 
mismatched 
alleles to 
dbSNP; missing 
by haplotype 
SNPs not in 
the HapMap 
were excluded 
from being 
used for 
imputation 
SNPs without 
chromosomal 
location; 
monomorphic 
SNPs; and SNPs 
whose genotype 
frequencies 
between differed 
by p<10-6 
 SNPs with no 
observed 
heterozygotes; 
SNPs with 
variance dosage 
< 0.01 excluded 
(~MAF 0.05); or 
SNPs not 
present in 
HapMap 
reference panel  
  SNPs without 
position 
assigned; 
poorly 
imputed SNPs 
(r2< 0.3) 
None 
N SNPs used 
for 
imputation 
329,804 338,598 704,588 460,584 306,665 378,163 491,875 356,359 869,224 
Imputation 
quality 
metrics 
r²hat>0.3 None none  variance dosage 
> 0.01  
Ratio of 
dosage 
variance to 
expected 
>0.3  
 R2 > 0.3 none 
N imputed 
SNPs for 
analysis 
2,408,991 2,543,013 2,516,204 2,543,888 2,334,835  2,543,887 2,586,725 2,252,229 2,748,910 
 
BIMBAM: http://stephenslab.uchicago.edu/software.html 
MaCH: http://www.sph.umich.edu/csg/abecasis/MaCH/index.html 
  
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated 
with carotid intima media thickness and plaque. (Supplementary Note) 
 
 38 
References 
 
1. Zannad, F. et al. Genetics strongly determines the wall thickness of the left and right carotid arteries. 
Hum Genet  103, 183-8 (1998). 
2. Jartti, L. et al. Population-based twin study of the effects of migration from Finland to Sweden on 
endothelial function and intima-media thickness. Arterioscler Thromb Vasc Biol  22, 832-7 (2002). 
3. Fox, C.S. et al. Genetic and environmental contributions to atherosclerosis phenotypes in men and 
women: heritability of carotid intima-media thickness in the Framingham Heart Study. Stroke  34, 397-
401 (2003). 
4. Swan, L., Birnie, D.H., Inglis, G., Connell, J.M. & Hillis, W.S. The determination of carotid intima 
medial thickness in adults--a population-based twin study. Atherosclerosis  166, 137-41 (2003). 
5. Moskau, S. et al. Heritability of carotid artery atherosclerotic lesions: an ultrasound study in 154 
families. Stroke  36, 5-8 (2005). 
6. Mayosi, B.M. et al. Genotype at the -174G/C polymorphism of the interleukin-6 gene is associated with 
common carotid artery intimal-medial thickness: family study and meta-analysis. Stroke  36, 2215-9 
(2005). 
7. Sayed-Tabatabaei, F.A. et al. Heritability of the function and structure of the arterial wall: findings of the 
Erasmus Rucphen Family (ERF) study. Stroke  36, 2351-6 (2005). 
8. Ryabikov, A. et al. Intrafamilial correlations of carotid intima-media thickness and flow-mediated 
dilation in a Siberian population. Am J Hypertens  20, 248-54 (2007). 
9. Rampersaud, E. et al. The association of coronary artery calcification and carotid artery intima-media 
thickness with distinct, traditional coronary artery disease risk factors in asymptomatic adults. Am J 
Epidemiol  168, 1016-23 (2008). 
10. Lange, L.A. et al. Heritability of carotid artery intima-medial thickness in type 2 diabetes. Stroke  33, 
1876-81 (2002). 
11. Zhao, J. et al. Heritability of carotid intima-media thickness: a twin study. Atherosclerosis  197, 814-20 
(2008). 
12. Duggirala, R., Gonzalez Villalpando, C., O'Leary, D.H., Stern, M.P. & Blangero, J. Genetic basis of 
variation in carotid artery wall thickness. Stroke  27, 833-7 (1996). 
13. Hunt, K.J. et al. Genetic basis of variation in carotid artery plaque in the San Antonio Family Heart 
Study. Stroke  33, 2775-80 (2002). 
14. Juo, S.H. et al. Genetic and environmental contributions to carotid intima-media thickness and obesity 
phenotypes in the Northern Manhattan Family Study. Stroke  35, 2243-7 (2004). 
15. Wang, D. et al. A genome-wide scan for carotid artery intima-media thickness: the Mexican-American 
Coronary Artery Disease family study. Stroke  36, 540-5 (2005). 
16. Kao, W.H. et al. Family history of type 2 diabetes is associated with increased carotid artery intimal-
medial thickness in Mexican Americans. Diabetes Care  28, 1882-9 (2005). 
17. Xiang, A.H. et al. Heritability of subclinical atherosclerosis in Latino families ascertained through a 
hypertensive parent. Arterioscler Thromb Vasc Biol  22, 843-8 (2002). 
18. Sacco, R.L. et al. Heritability and linkage analysis for carotid intima-media thickness: the family study of 
stroke risk and carotid atherosclerosis. Stroke  40, 2307-12 (2009). 
19. Dong, C. et al. Genomewide linkage and peakwide association analyses of carotid plaque in Caribbean 
Hispanics. Stroke  41, 2750-6 (2010). 
20. North, K.E. et al. Heritability of carotid artery structure and function: the Strong Heart Family Study. 
Arterioscler Thromb Vasc Biol  22, 1698-703 (2002). 
21. Manolio, T.A., Boerwinkle, E., O'Donnell, C.J. & Wilson, A.F. Genetics of ultrasonographic carotid 
atherosclerosis. Arterioscler Thromb Vasc Biol  24, 1567-77 (2004). 
22. Psaty, B.M. et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
Consortium: Design of Prospective Meta-Analyses of Genome-Wide Association Studies From 5 
Cohorts. Circ Cardiovasc Genet  2, 73-80 (2009). 
23. Harris, T.B. et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied 
phenomics. Am J Epidemiol  165, 1076-87 (2007). 
24. Post, W. et al. Determinants of coronary artery and aortic calcification in the Old Order Amish. 
Circulation  115, 717-24 (2007). 
25. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. 
Am J Epidemiol  129, 687-702 (1989). 
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated 
with carotid intima media thickness and plaque. (Supplementary Note) 
 
 39 
26. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. 
Am J Hum Genet  81, 559-75 (2007). 
27. Price, A.L. et al. Principal components analysis corrects for stratification in genome-wide association 
studies. Nat Genet  38, 904-9 (2006). 
28. Fried, L.P. et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol  1, 263-76 
(1991). 
29. Servin, B. & Stephens, M. Imputation-based analysis of association studies: candidate regions and 
quantitative traits. PLoS Genet  3, e114 (2007). 
30. Aulchenko, Y.S. et al. Linkage disequilibrium in young genetically isolated Dutch population. Eur J 
Hum Genet  12, 527-34 (2004). 
31. Dawber, T.R. & Kannel, W.B. The Framingham study. An epidemiological approach to coronary heart 
disease. Circulation  34, 553-5 (1966). 
32. Kannel, W.B., Feinleib, M., McNamara, P.M., Garrison, R.J. & Castelli, W.P. An investigation of 
coronary heart disease in families. The Framingham offspring study. Am J Epidemiol  110, 281-90 
(1979). 
33. Splansky, G.L. et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute's 
Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol  165, 1328-35 
(2007). 
34. Hofman, A. et al. The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol  24, 553-72 
(2009). 
35. Pilia, G. et al. Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet  2, 
e132 (2006). 
36. Epstein, M.P., Duren, W.L. & Boehnke, M. Improved inference of relationship for pairs of individuals. 
Am J Hum Genet  67, 1219-31 (2000). 
37. Chen, W.M. & Abecasis, G.R. Family-based association tests for genomewide association scans. Am J 
Hum Genet  81, 913-26 (2007). 
38. John, U. et al. Study of Health In Pomerania (SHIP): a health examination survey in an east German 
region: objectives and design. Soz Praventivmed  46, 186-94 (2001). 
39. Schmidt, R. et al. Assessment of cerebrovascular risk profiles in healthy persons: definition of research 
goals and the Austrian Stroke Prevention Study (ASPS). Neuroepidemiology  13, 308-13 (1994). 
40. Sitzer, M. et al. C-reactive protein and carotid intimal medial thickness in a community population. J 
Cardiovasc Risk  9, 97-103 (2002). 
41. Browning, B.L. & Browning, S.R. A unified approach to genotype imputation and haplotype-phase 
inference for large data sets of trios and unrelated individuals. Am J Hum Genet  84, 210-23 (2009). 
42. Raitakari, O.T. et al. Cohort profile: the cardiovascular risk in Young Finns Study. Int J Epidemiol  37, 
1220-6 (2008). 
43. Preuss, M. et al. Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis 
(CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases 
and 60 000 controls. Circ Cardiovasc Genet  3, 475-83 (2010). 
44. Schunkert, H. et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary 
artery disease. Nat Genet 43, 333-8 (2011). 
45. Heiss, G. et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations 
with cardiovascular risk factors in the ARIC study. Am J Epidemiol  134, 250-6 (1991). 
46. Espeland, M.A. et al. Analysis strategies for serial multivariate ultrasonographic data that are 
incomplete. Stat Med  11, 1041-56 (1992). 
47. Hunt, K.J. et al. Acoustic shadowing on B-mode ultrasound of the carotid artery predicts ischemic 
stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke  32, 1120-6 (2001). 
48. O'Leary, D.H. et al. Use of sonography to evaluate carotid atherosclerosis in the elderly. The 
Cardiovascular Health Study. CHS Collaborative Research Group. Stroke  22, 1155-63 (1991). 
49. Bots, M.L., Hoes, A.W., Koudstaal, P.J., Hofman, A. & Grobbee, D.E. Common carotid intima-media 
thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation  96, 1432-7 
(1997). 
50. Fox, C.S. et al. Genomewide linkage analysis for internal carotid artery intimal medial thickness: 
evidence for linkage to chromosome 12. Am J Hum Genet  74, 253-61 (2004). 
51. O'Leary, D.H. et al. Distribution and correlates of sonographically detected carotid artery disease in the 
Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke  23, 1752-60 (1992). 
Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated 
with carotid intima media thickness and plaque. (Supplementary Note) 
 
 40 
52. Elosua, R. et al. Association of APOE genotype with carotid atherosclerosis in men and women: the 
Framingham Heart Study. J Lipid Res  45, 1868-75 (2004). 
53. Hollander, M. et al. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in 
asymptomatic elderly: the Rotterdam study. Circulation  105, 2872-7 (2002). 
54. Scuteri, A. et al. Age- and gender-specific awareness, treatment, and control of cardiovascular risk 
factors and subclinical vascular lesions in a founder population: The SardiNIA Study. Nutr Metab 
Cardiovasc Dis  (2009). 
55. Scuteri, A. et al. The central arterial burden of the metabolic syndrome is similar in men and women: 
the SardiNIA Study. Eur Heart J  (2009). 
56. Ludemann, J. et al. [Methods for quality assurance of medical examination in epidemiological field 
studies: the "Study of Health in Pomerania" (SHIP)]. Gesundheitswesen  62, 234-43 (2000). 
57. Schmidt, R. et al. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of 
the Austrian Stroke Prevention Study. Stroke  37, 2910-6 (2006). 
58. Aulchenko, Y.S., Ripke, S., Isaacs, A. & van Duijn, C.M. GenABEL: an R library for genome-wide 
association analysis. Bioinformatics  23, 1294-6 (2007). 
 
 
